2024_R&D_의약품_e – (주)셀인바이오

Medicine

We carry out joint research projects to develop efficient new drugs by introducing technologies from universities and research institutes. We are currently developing a biological drug to treat rheumarthritis based on cytokine. It is a first-in-class drug to overcome the limitations of the old antibody drugs including their side effects and maintain the homeostasis of immunity in the human body.

Project-1

We developed a rheumarthritis drug based on a new drug technology(CIB1401H).

-It is based on a new mechanism to overcome the shortcomings of anti-TNF-α therapy.

-It is a cytokine substance(CIB1401H) of excellent biological safety.

-It suppresses Th1/Th17 differentiation and macrophase activation.

–Patent: KR1016251120000 / US 9737588B2 / US 9943567B2 /WO 2014171721

-Paper: 1. Therapeutic Effect of Exogenous Truncated IK Protein in Inflammatory Arthritis, Int. J. Mol. Sci.(2017)

2. IK acts as an immunoregulator of inflammatory arthritis by suppressing TH17 cell differentiation and macrophage activation, Scientific Reports.(2017)

3. Homology Modeling and Optimized Expression of Truncated IK Protein, tIK, as an Anti-Inflammatory Peptide, Molecules (2020)

4. Suppressive Effects of a Truncated Inhibitor K562 Protein-Derived Peptide on Two Proinflammatory Cytokines, IL-17 and TNF-α, J. Microbiol. Biotechnol. (2020)

CELLINBIO

CELLINBIO l CEO : Myung Ok Lee l Adress : 103-1307 (Digital Empire II, Sindong) Sinwon-ro 88, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16681 Korea (South) TEL : +82-31-695-7960 l FAX : +82-31-695-7986 l E-Mail : cellinbio@cellinbio.com l Business license number : 135-81-99337 l Computer system manger : Su-jin Lee